{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04018313",
      "orgStudyIdInfo": {
        "id": "CT-P39 1.1"
      },
      "organization": {
        "fullName": "Celltrion",
        "class": "INDUSTRY"
      },
      "briefTitle": "To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects",
      "officialTitle": "A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects"
    },
    "statusModule": {
      "statusVerifiedDate": "2021-09",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-05-28",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-03-27",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-04-30",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2019-07-09",
      "studyFirstSubmitQcDate": "2019-07-10",
      "studyFirstPostDateStruct": {
        "date": "2019-07-12",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2022-06-30",
      "resultsFirstSubmitQcDate": "2022-06-30",
      "resultsFirstPostDateStruct": {
        "date": "2023-05-11",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-06-30",
      "lastUpdatePostDateStruct": {
        "date": "2023-05-11",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Celltrion",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects"
    },
    "conditionsModule": {
      "conditions": [
        "Healthy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "OTHER",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 176,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "CT-P39 (Part 1)",
          "type": "EXPERIMENTAL",
          "description": "150 mg/mL, Solution for injection in PFS",
          "interventionNames": [
            "Biological: CT-P39"
          ]
        },
        {
          "label": "EU-approved Xolair (Part 1)",
          "type": "ACTIVE_COMPARATOR",
          "description": "150 mg/mL, Solution for injection in PFS",
          "interventionNames": [
            "Biological: EU-approved Xolair"
          ]
        },
        {
          "label": "CT-P39 (Part 2)",
          "type": "EXPERIMENTAL",
          "description": "150 mg/mL, Solution for injection in PFS",
          "interventionNames": [
            "Biological: CT-P39"
          ]
        },
        {
          "label": "EU-approved Xolair (Part 2)",
          "type": "ACTIVE_COMPARATOR",
          "description": "150 mg/mL, Solution for injection in PFS",
          "interventionNames": [
            "Biological: EU-approved Xolair"
          ]
        },
        {
          "label": "US-licensed Xolair (Part 2)",
          "type": "ACTIVE_COMPARATOR",
          "description": "150 mg/mL, Solution for injection in PFS",
          "interventionNames": [
            "Biological: US-licensed Xolair"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "CT-P39",
          "description": "150 mg/mL, Solution for injection in PFS",
          "armGroupLabels": [
            "CT-P39 (Part 1)"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "EU-approved Xolair",
          "description": "150 mg/mL, Solution for injection in PFS",
          "armGroupLabels": [
            "EU-approved Xolair (Part 1)"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "CT-P39",
          "description": "150 mg/mL, Solution for injection in PFS",
          "armGroupLabels": [
            "CT-P39 (Part 2)"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "EU-approved Xolair",
          "description": "150 mg/mL, Solution for injection in PFS",
          "armGroupLabels": [
            "EU-approved Xolair (Part 2)"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "US-licensed Xolair",
          "description": "150 mg/mL, Solution for injection in PFS",
          "armGroupLabels": [
            "US-licensed Xolair (Part 2)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Pharmacokinetic Outcome Measures [AUC0-inf] for Part 2",
          "description": "Area Under the concentration-time Curve from time zero to infinity (AUC0-inf) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [AUC0-last] for Part 2",
          "description": "Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-last) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [Cmax] for Part 2",
          "description": "Maximum serum concentration (Cmax) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "timeFrame": "up to day 127"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pharmacokinetic Outcome Measures [Tmax] for Part 1& Part 2",
          "description": "To assess Time to Cmax (Tmax) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [t1/2] for Part 1& Part 2",
          "description": "To assess Terminal half-life (t1/2) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacodynamics Outcome Measures [Cmin of Free IgE] for Part 1 & Part 2",
          "description": "To assess the minimum observed concentration (Cmin) of Free IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacodynamic Outcome Measures [Tmin of Free IgE] for Part 1 & Part 2",
          "description": "To assess the Time to Cmin (Tmin) of Free IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "Up to day 127"
        },
        {
          "measure": "Pharmacodynamic Outcome Measures [Cmax of Total IgE] for Part 1 & Part 2",
          "description": "To assess the maximum observed concentration (Cmax) of total IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "up to day 127"
        },
        {
          "measure": "Pharmacodynamic Outcome Measures [Tmax of Total IgE] for Part 1 & Part 2",
          "description": "To assess the Time to Cmax (Tmax) of total IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "timeFrame": "up to day 127"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy subject (male or female) between the ages of 18 and 55 years.\n* Subject with a body weight of \\> 40 kg and ≤ 90 kg and a BMI between 18.0 kg/m2 and 32.0 kg/m2(both inclusive).\n* Subject with a total IgE level of ≤ 100 IU/mL.\n\nExclusion Criteria:\n\n* Subject has a medical history and/or current presence of disease including one or more of the allergic reaction.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "SungHyun Kim",
          "affiliation": "Celltrion",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Phase 1 unit",
          "city": "Herston",
          "state": "Queensland",
          "zip": "4006",
          "country": "Australia",
          "geoPoint": {
            "lat": -27.44453,
            "lon": 153.01852
          }
        },
        {
          "facility": "Phase 1 unit",
          "city": "Adelaide",
          "state": "South Australia",
          "zip": "5000",
          "country": "Australia",
          "geoPoint": {
            "lat": -34.92866,
            "lon": 138.59863
          }
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "CT-P39 (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
        },
        {
          "id": "FG001",
          "title": "EU-approved Xolair (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
        },
        {
          "id": "FG002",
          "title": "CT-P39 (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
        },
        {
          "id": "FG003",
          "title": "EU-approved Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
        },
        {
          "id": "FG004",
          "title": "US-licensed Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "15"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "15"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "47"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "49"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "50"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "14"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "14"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "46"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "47"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "49"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "ITT set: all subjects enrolled and randomly assigned to receive a dose of any study drug, regardless of whether or not any study drug was administered.",
      "groups": [
        {
          "id": "BG000",
          "title": "CT-P39 (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
        },
        {
          "id": "BG001",
          "title": "EU-approved Xolair (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
        },
        {
          "id": "BG002",
          "title": "CT-P39 (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
        },
        {
          "id": "BG003",
          "title": "EU-approved Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
        },
        {
          "id": "BG004",
          "title": "US-licensed Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
        },
        {
          "id": "BG005",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "15"
            },
            {
              "groupId": "BG001",
              "value": "15"
            },
            {
              "groupId": "BG002",
              "value": "47"
            },
            {
              "groupId": "BG003",
              "value": "49"
            },
            {
              "groupId": "BG004",
              "value": "50"
            },
            {
              "groupId": "BG005",
              "value": "176"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "26.7",
                      "spread": "6.31"
                    },
                    {
                      "groupId": "BG001",
                      "value": "26.9",
                      "spread": "9.11"
                    },
                    {
                      "groupId": "BG002",
                      "value": "28.2",
                      "spread": "8.81"
                    },
                    {
                      "groupId": "BG003",
                      "value": "32.1",
                      "spread": "11.65"
                    },
                    {
                      "groupId": "BG004",
                      "value": "30.3",
                      "spread": "10.09"
                    },
                    {
                      "groupId": "BG005",
                      "value": "29.6",
                      "spread": "9.99"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "8"
                    },
                    {
                      "groupId": "BG001",
                      "value": "8"
                    },
                    {
                      "groupId": "BG002",
                      "value": "28"
                    },
                    {
                      "groupId": "BG003",
                      "value": "27"
                    },
                    {
                      "groupId": "BG004",
                      "value": "30"
                    },
                    {
                      "groupId": "BG005",
                      "value": "101"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "7"
                    },
                    {
                      "groupId": "BG001",
                      "value": "7"
                    },
                    {
                      "groupId": "BG002",
                      "value": "19"
                    },
                    {
                      "groupId": "BG003",
                      "value": "22"
                    },
                    {
                      "groupId": "BG004",
                      "value": "20"
                    },
                    {
                      "groupId": "BG005",
                      "value": "75"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    },
                    {
                      "groupId": "BG001",
                      "value": "5"
                    },
                    {
                      "groupId": "BG002",
                      "value": "6"
                    },
                    {
                      "groupId": "BG003",
                      "value": "6"
                    },
                    {
                      "groupId": "BG004",
                      "value": "8"
                    },
                    {
                      "groupId": "BG005",
                      "value": "30"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "9"
                    },
                    {
                      "groupId": "BG001",
                      "value": "7"
                    },
                    {
                      "groupId": "BG002",
                      "value": "40"
                    },
                    {
                      "groupId": "BG003",
                      "value": "39"
                    },
                    {
                      "groupId": "BG004",
                      "value": "39"
                    },
                    {
                      "groupId": "BG005",
                      "value": "134"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "4"
                    },
                    {
                      "groupId": "BG004",
                      "value": "3"
                    },
                    {
                      "groupId": "BG005",
                      "value": "12"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race/Ethnicity, Customized",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "title": "American Indian or Alaska native",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "3"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Asian",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "7"
                    },
                    {
                      "groupId": "BG003",
                      "value": "6"
                    },
                    {
                      "groupId": "BG004",
                      "value": "8"
                    },
                    {
                      "groupId": "BG005",
                      "value": "21"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Black or African American",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "3"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "4"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Australian Aborigine/Torres Strait Islander",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Pacific Islander",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "White",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    },
                    {
                      "groupId": "BG001",
                      "value": "12"
                    },
                    {
                      "groupId": "BG002",
                      "value": "36"
                    },
                    {
                      "groupId": "BG003",
                      "value": "38"
                    },
                    {
                      "groupId": "BG004",
                      "value": "40"
                    },
                    {
                      "groupId": "BG005",
                      "value": "138"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Other",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    },
                    {
                      "groupId": "BG003",
                      "value": "2"
                    },
                    {
                      "groupId": "BG004",
                      "value": "2"
                    },
                    {
                      "groupId": "BG005",
                      "value": "8"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "Australia",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "15"
                    },
                    {
                      "groupId": "BG001",
                      "value": "15"
                    },
                    {
                      "groupId": "BG002",
                      "value": "47"
                    },
                    {
                      "groupId": "BG003",
                      "value": "49"
                    },
                    {
                      "groupId": "BG004",
                      "value": "50"
                    },
                    {
                      "groupId": "BG005",
                      "value": "176"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Body mass index at screening",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "kg/m2",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "22.93",
                      "spread": "2.525"
                    },
                    {
                      "groupId": "BG001",
                      "value": "23.65",
                      "spread": "2.306"
                    },
                    {
                      "groupId": "BG002",
                      "value": "23.90",
                      "spread": "3.042"
                    },
                    {
                      "groupId": "BG003",
                      "value": "23.19",
                      "spread": "2.864"
                    },
                    {
                      "groupId": "BG004",
                      "value": "23.71",
                      "spread": "2.980"
                    },
                    {
                      "groupId": "BG005",
                      "value": "23.54",
                      "spread": "2.866"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Pharmacokinetic Outcome Measures [AUC0-inf] for Part 2",
          "description": "Area Under the concentration-time Curve from time zero to infinity (AUC0-inf) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "populationDescription": "PK set: all randomly assigned subjects who receive a complete dose of study drug and provide at least one post-treatment serum concentration above the lower limit of quantification for omalizumab.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "day*μg/mL",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG002",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "46"
                },
                {
                  "groupId": "OG001",
                  "value": "49"
                },
                {
                  "groupId": "OG002",
                  "value": "50"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "910.9",
                      "spread": "278.57"
                    },
                    {
                      "groupId": "OG001",
                      "value": "897.7",
                      "spread": "270.25"
                    },
                    {
                      "groupId": "OG002",
                      "value": "926.3",
                      "spread": "273.30"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "105.62",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "95.91",
              "ciUpperLimit": "116.31"
            },
            {
              "groupIds": [
                "OG000",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "98.72",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "89.76",
              "ciUpperLimit": "108.58"
            },
            {
              "groupIds": [
                "OG001",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "93.47",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "85.09",
              "ciUpperLimit": "102.68"
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Pharmacokinetic Outcome Measures [AUC0-last] for Part 2",
          "description": "Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-last) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "populationDescription": "PK set: all randomly assigned subjects who receive a complete dose of study drug and provide at least one post-treatment serum concentration above the lower limit of quantification for omalizumab.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "day*μg/mL",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG002",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "47"
                },
                {
                  "groupId": "OG001",
                  "value": "49"
                },
                {
                  "groupId": "OG002",
                  "value": "50"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "846",
                      "spread": "251.87"
                    },
                    {
                      "groupId": "OG001",
                      "value": "843.8",
                      "spread": "248.04"
                    },
                    {
                      "groupId": "OG002",
                      "value": "850.0",
                      "spread": "213.13"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "104.00",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "94.96",
              "ciUpperLimit": "113.89"
            },
            {
              "groupIds": [
                "OG000",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "99.30",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "90.79",
              "ciUpperLimit": "108.61"
            },
            {
              "groupIds": [
                "OG001",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "95.48",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "87.36",
              "ciUpperLimit": "104.37"
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Pharmacokinetic Outcome Measures [Cmax] for Part 2",
          "description": "Maximum serum concentration (Cmax) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects (CT-P39 to EU-approved Xolair, CT-P39 to US-licensed Xolair, and EU-approved Xolair to US-licensed Xolair)",
          "populationDescription": "PK set: all randomly assigned subjects who receive a complete dose of study drug and provide at least one post-treatment serum concentration above the lower limit of quantification for omalizumab.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "μg/mL",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG002",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "47"
                },
                {
                  "groupId": "OG001",
                  "value": "49"
                },
                {
                  "groupId": "OG002",
                  "value": "50"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20.08",
                      "spread": "5.9940"
                    },
                    {
                      "groupId": "OG001",
                      "value": "18.24",
                      "spread": "4.9981"
                    },
                    {
                      "groupId": "OG002",
                      "value": "19.43",
                      "spread": "5.4159"
                    }
                  ]
                }
              ]
            }
          ],
          "analyses": [
            {
              "groupIds": [
                "OG000",
                "OG001"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "113.14",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "103.15",
              "ciUpperLimit": "124.11"
            },
            {
              "groupIds": [
                "OG000",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "103.88",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "94.83",
              "ciUpperLimit": "113.80"
            },
            {
              "groupIds": [
                "OG001",
                "OG002"
              ],
              "groupDescription": "The statistical analysis of the log-transformed primary endpoints was based on an ANCOVA model with treatment as fixed effect and baseline body weight, total IgE level and sex as covariates.",
              "nonInferiorityType": "EQUIVALENCE",
              "nonInferiorityComment": "The similarity of PK between CT-P39 versus EU-approved Xolair, CT-P39 versus US-licensed Xolair, and EU-approved Xolair versus US-licensed Xolair was concluded if the 90% confidence intervals (CIs) of the ratios of geometric means of each comparison are entirely contained within 80% to 125% for AUC0-inf, AUC0-last, and Cmax.",
              "paramType": "Ratio of geometric least square means",
              "paramValue": "91.82",
              "ciPctValue": "90",
              "ciNumSides": "TWO_SIDED",
              "ciLowerLimit": "83.87",
              "ciUpperLimit": "100.52"
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacokinetic Outcome Measures [Tmax] for Part 1& Part 2",
          "description": "To assess Time to Cmax (Tmax) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PK set: all randomly assigned subjects who receive a complete dose of study drug and provide at least one post-treatment serum concentration above the lower limit of quantification for omalizumab.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "day",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "15"
                },
                {
                  "groupId": "OG001",
                  "value": "15"
                },
                {
                  "groupId": "OG002",
                  "value": "47"
                },
                {
                  "groupId": "OG003",
                  "value": "49"
                },
                {
                  "groupId": "OG004",
                  "value": "50"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "7.178",
                      "lowerLimit": "5.04",
                      "upperLimit": "56.27"
                    },
                    {
                      "groupId": "OG001",
                      "value": "7.244",
                      "lowerLimit": "3.00",
                      "upperLimit": "14.17"
                    },
                    {
                      "groupId": "OG002",
                      "value": "7.098",
                      "lowerLimit": "2.00",
                      "upperLimit": "14.26"
                    },
                    {
                      "groupId": "OG003",
                      "value": "7.306",
                      "lowerLimit": "3.00",
                      "upperLimit": "18.26"
                    },
                    {
                      "groupId": "OG004",
                      "value": "7.183",
                      "lowerLimit": "3.00",
                      "upperLimit": "21.17"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacokinetic Outcome Measures [t1/2] for Part 1& Part 2",
          "description": "To assess Terminal half-life (t1/2) of CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PK set: all randomly assigned subjects who receive a complete dose of study drug and provide at least one post-treatment serum concentration above the lower limit of quantification for omalizumab.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "day",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "15"
                },
                {
                  "groupId": "OG001",
                  "value": "15"
                },
                {
                  "groupId": "OG002",
                  "value": "46"
                },
                {
                  "groupId": "OG003",
                  "value": "49"
                },
                {
                  "groupId": "OG004",
                  "value": "50"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "29.75",
                      "spread": "3.9477"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28.77",
                      "spread": "5.0315"
                    },
                    {
                      "groupId": "OG002",
                      "value": "29.30",
                      "spread": "9.5158"
                    },
                    {
                      "groupId": "OG003",
                      "value": "27.69",
                      "spread": "5.5603"
                    },
                    {
                      "groupId": "OG004",
                      "value": "28.63",
                      "spread": "6.6290"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacodynamics Outcome Measures [Cmin of Free IgE] for Part 1 & Part 2",
          "description": "To assess the minimum observed concentration (Cmin) of Free IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PD set: all randomly assigned subjects who receive a complete dose of study drug and have at least one post-treatment free IgE or total IgE concentration above the lower limit of quantification.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "IU/mL",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "13"
                },
                {
                  "groupId": "OG001",
                  "value": "11"
                },
                {
                  "groupId": "OG002",
                  "value": "31"
                },
                {
                  "groupId": "OG003",
                  "value": "38"
                },
                {
                  "groupId": "OG004",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.1538",
                      "spread": "1.12963"
                    },
                    {
                      "groupId": "OG001",
                      "value": "3.4613",
                      "spread": "1.43457"
                    },
                    {
                      "groupId": "OG002",
                      "value": "3.5267",
                      "spread": "1.45275"
                    },
                    {
                      "groupId": "OG003",
                      "value": "3.5590",
                      "spread": "1.56235"
                    },
                    {
                      "groupId": "OG004",
                      "value": "3.7002",
                      "spread": "1.69613"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacodynamic Outcome Measures [Tmin of Free IgE] for Part 1 & Part 2",
          "description": "To assess the Time to Cmin (Tmin) of Free IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PD set: all randomly assigned subjects who receive a complete dose of study drug and have at least one post-treatment free IgE or total IgE concentration above the lower limit of quantification.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "day",
          "timeFrame": "Up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "13"
                },
                {
                  "groupId": "OG001",
                  "value": "11"
                },
                {
                  "groupId": "OG002",
                  "value": "31"
                },
                {
                  "groupId": "OG003",
                  "value": "38"
                },
                {
                  "groupId": "OG004",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.000",
                      "lowerLimit": "0.50",
                      "upperLimit": "10.09"
                    },
                    {
                      "groupId": "OG001",
                      "value": "5.196",
                      "lowerLimit": "1.00",
                      "upperLimit": "126.25"
                    },
                    {
                      "groupId": "OG002",
                      "value": "3.000",
                      "lowerLimit": "0.25",
                      "upperLimit": "21.21"
                    },
                    {
                      "groupId": "OG003",
                      "value": "5.051",
                      "lowerLimit": "0.25",
                      "upperLimit": "70.17"
                    },
                    {
                      "groupId": "OG004",
                      "value": "3.002",
                      "lowerLimit": "0.25",
                      "upperLimit": "41.07"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacodynamic Outcome Measures [Cmax of Total IgE] for Part 1 & Part 2",
          "description": "To assess the maximum observed concentration (Cmax) of total IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PD set: all randomly assigned subjects who receive a complete dose of study drug and have at least one post-treatment free IgE or total IgE concentration above the lower limit of quantification.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "IU/mL",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "15"
                },
                {
                  "groupId": "OG001",
                  "value": "15"
                },
                {
                  "groupId": "OG002",
                  "value": "46"
                },
                {
                  "groupId": "OG003",
                  "value": "49"
                },
                {
                  "groupId": "OG004",
                  "value": "49"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "241.5333",
                      "spread": "156.50234"
                    },
                    {
                      "groupId": "OG001",
                      "value": "165.2000",
                      "spread": "122.59702"
                    },
                    {
                      "groupId": "OG002",
                      "value": "245.2391",
                      "spread": "223.24856"
                    },
                    {
                      "groupId": "OG003",
                      "value": "174.2857",
                      "spread": "145.17432"
                    },
                    {
                      "groupId": "OG004",
                      "value": "219.5714",
                      "spread": "187.41287"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pharmacodynamic Outcome Measures [Tmax of Total IgE] for Part 1 & Part 2",
          "description": "To assess the Time to Cmax (Tmax) of total IgE in CT-P39, EU-approved Xolair, and US-licensed Xolair in healthy subjects",
          "populationDescription": "PD set: all randomly assigned subjects who receive a complete dose of study drug and have at least one post-treatment free IgE or total IgE concentration above the lower limit of quantification.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "day",
          "timeFrame": "up to day 127",
          "groups": [
            {
              "id": "OG000",
              "title": "CT-P39 (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG001",
              "title": "EU-approved Xolair (Part 1)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG002",
              "title": "CT-P39 (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection."
            },
            {
              "id": "OG003",
              "title": "EU-approved Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection"
            },
            {
              "id": "OG004",
              "title": "US-licensed Xolair (Part 2)",
              "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL Solution for injection."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "15"
                },
                {
                  "groupId": "OG001",
                  "value": "15"
                },
                {
                  "groupId": "OG002",
                  "value": "46"
                },
                {
                  "groupId": "OG003",
                  "value": "49"
                },
                {
                  "groupId": "OG004",
                  "value": "49"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "28.263",
                      "lowerLimit": "20.99",
                      "upperLimit": "69.17"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28.167",
                      "lowerLimit": "14.19",
                      "upperLimit": "56.10"
                    },
                    {
                      "groupId": "OG002",
                      "value": "28.191",
                      "lowerLimit": "3.00",
                      "upperLimit": "70.13"
                    },
                    {
                      "groupId": "OG003",
                      "value": "28.156",
                      "lowerLimit": "14.01",
                      "upperLimit": "71.07"
                    },
                    {
                      "groupId": "OG004",
                      "value": "28.087",
                      "lowerLimit": "10.18",
                      "upperLimit": "73.07"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "All AEs were collected from the date the ICF was signed and AE reporting continued until the end of the subject's participation in this study (up to Day 127).",
      "description": "Only treatment-emergent adverse events and treatment-emergent serious adverse events were summarized",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "CT-P39 (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 15,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 15,
          "otherNumAffected": 4,
          "otherNumAtRisk": 15
        },
        {
          "id": "EG001",
          "title": "EU-approved Xolair (Part 1)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 15,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 15,
          "otherNumAffected": 7,
          "otherNumAtRisk": 15
        },
        {
          "id": "EG002",
          "title": "CT-P39 (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of CT-P39 via pre-filled syringe (PFS).\n\nCT-P39: 150 mg/mL Solution for injection.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 47,
          "seriousNumAffected": 1,
          "seriousNumAtRisk": 47,
          "otherNumAffected": 20,
          "otherNumAtRisk": 47
        },
        {
          "id": "EG003",
          "title": "EU-approved Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of EU-approved Xolair via pre-filled syringe (PFS).\n\nEU-approved Xolair: 150 mg/mL Solution for injection.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 49,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 49,
          "otherNumAffected": 26,
          "otherNumAtRisk": 49
        },
        {
          "id": "EG004",
          "title": "US-licensed Xolair (Part 2)",
          "description": "Healthy subjects were administered single subcutaneous (SC) injection of US-licensed Xolair via pre-filled syringe (PFS).\n\nUS-licensed Xolair: 150 mg/mL, Solution for injection.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 50,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 50,
          "otherNumAffected": 31,
          "otherNumAtRisk": 50
        }
      ],
      "seriousEvents": [
        {
          "term": "Head injury",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 50
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 6,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Catheter site pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Injection site reaction",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 8,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 5,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 6,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Catheter site irritation",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 5,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 11,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 10,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 15,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Myalgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 50
            }
          ]
        },
        {
          "term": "Rhinitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA Version 22.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 15
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 47
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 49
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 50
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "OTHER",
        "restrictiveAgreement": true,
        "otherDetails": "A confidentiality and non-disclosure agreement (CDA) was executed between Celltrion, Inc. and some PIs who have participated in publications funded by the sponsor for academic purposes for a period that is more than 180 days from the time submitted to the sponsor for review."
      },
      "pointOfContact": {
        "title": "Keumyoung Ahn/Head of Clinical Planning 2 Department",
        "organization": "Celltrion. Inc",
        "email": "Keumyoung.ahn@celltrion.com",
        "phone": "+82 32 850 4190"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2020-04-20",
          "uploadDate": "2022-06-16T04:03",
          "filename": "Prot_000.pdf",
          "size": 997000
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2021-06-01",
          "uploadDate": "2022-06-16T04:04",
          "filename": "SAP_001.pdf",
          "size": 1177862
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    }
  },
  "hasResults": true
}